<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Current Report Pursuant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported)
February 7, 2013</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRESSURE BIOSCIENCES, INC.</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center; background-color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">MASSACHUSETTS</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center; background-color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center">&nbsp; (State or Other Jurisdiction
of Incorporation)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">&nbsp; 0-21615</TD>
    <TD STYLE="width: 12%; border-bottom: white 9pt double; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">&nbsp; 04-2652826</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp; (Commission File Number)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;&nbsp; (IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">&nbsp; 14 Norfolk Avenue, South Easton, MA</TD>
    <TD STYLE="width: 12%; border-bottom: white 9pt double; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">02375</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;&nbsp; (Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(508) 230-1828</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center; background-color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center">(Registrant&#8217;s Telephone Number,
Including Area Code)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center; background-color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( <I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-family: Wingdings">o</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-family: Wingdings">o</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-family: Wingdings">o</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font-family: Wingdings"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/0.05pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><B>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2013, R. Wayne Fritzsche
resigned as a director of Pressure BioSciences, Inc. (the &#8220;Company&#8221;). Mr. Fritzsche informed the Board of Directors
(the &#8220;Board&#8221;) of the Company that he was resigning to pursue full-time employment with the Company and that his reasons
for resigning were not the result of any disagreement with the Company. The Board accepted Mr. Fritzsche&#8217;s resignation.</P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a recommendation by the Nominating
Committee of the Board, on February 7, 2013 the Board appointed Dr. Michael S. &#8220;Mickey&#8221; Urdea as a director to fill
the vacancy created by Mr. Fritzsche&#8217;s resignation, effective as of February 8, 2013. Dr. Urdea will be a Class III director
with a term expiring at the Company&#8217;s 2014 annual meeting of shareholders.</P>

<P STYLE="font: 11pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Dr. Urdea will receive an annual Board retainer in the amount of
$30,000. Dr. Urdea will also receive $20,000 annually to develop and lead the Company&#8217;s Scientific Advisory Board (the &#8220;SBA&#8221;).
Dr. Urdea has agreed to accrue such fees until such time in the future that the Board determines that the overall financial and
cash position of the Company will allow payments of such amounts. The Company and Dr. Urdea have further agreed that in lieu of
payment of a portion of his annual Board and SBA related fees for his first year of service, $12,500 of the annual Board retainer
and $10,000 of the annual SBA related fees would be converted into the Company&#8217;s private placement of units consisting of
Series J Convertible Preferred Stock and warrants to purchase restricted common stock pursuant to the terms of the private placement.
In addition, as a non-employee director, Dr. Urdea was granted options to purchase 25,000 shares of the Company&#8217;s common
stock upon appointment as a director, which options vested immediately upon grant, and 25,000 restricted shares of the Company&#8217;s
common stock, which restricted shares will vest on a monthly basis during his first year of service.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/11.35pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Urdea has devoted his 30-year career
to human diagnostics in a variety of capacities. He has been involved in the discovery of new biomarkers, the development of new
technologies for biomarker discovery, validation and commercialization, diagnostic test development, manufacturing and marketing,
and the management of companies involved in these activities. Dr. Urdea founded and is a Managing Partner for Halteres Associates,
a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based
diagnostics company involved in preventative personalized medicine. Tethys&#8217; first product was the protein-based PreDx Diabetes
Risk Score Test, which was introduced in 2008. Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for
Health, an organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. He serves
as an expert consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number
of biotechnology, diagnostics, venture capital and philanthropic organizations.</P>

<P STYLE="font: 11pt/11.35pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to his current business activities,
Dr. Urdea founded the Nucleic Acid Diagnostics group at Chiron Corporation, and with colleagues, invented branched DNA molecules
for amplification of signal in nucleic acid complexes. Application of this technology resulted in the first commercial products
for quantification of human hepatitis B, hepatitis C, and human immunodeficiency viruses (HBV, HCV, and HIV, respectively). He
then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He was also a member
of the Bill and Melinda Gates Foundation Diagnostic Forum.</P>

<P STYLE="font: 11pt/11.35pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Urdea is an author on nearly 200
peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued
and pending patents. He received his BS</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/11.35pt Times New Roman, Times, Serif; margin: 0; text-align: justify">in Biology and Chemistry from Northern
Arizona University in Flagstaff and his Ph.D in Biochemistry from Washington State University in Pullman.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">A copy of the press release that the Company issued on February
12, 2013 announcing the appointment of Dr. Urdea is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Item 9.01 &#9;Financial Statements and Exhibits </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U> Exhibits</U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
<BR>
</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt; font-weight: bold">Exhibit Number&nbsp;</TD>
    <TD STYLE="width: 90%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt; font-weight: bold">Exhibit Description&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">99.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">Press release dated February 12, 2013 of Pressure BioSciences, Inc. furnished herewith.</TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; padding-right: 0.8pt; font: 11pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-right: 0.8pt; font: 11pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 52%; padding-right: 0.8pt; font: 11pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-right: 0.8pt">Dated: February 12, 2013</TD>
    <TD COLSPAN="2" STYLE="font: bold 11pt Times New Roman, Times, Serif; padding-right: 1.8pt">PRESSURE BIOSCIENCES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">&nbsp;/s/Richard Schumacher</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-right: 0.8pt">By:&nbsp;&nbsp;</TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-right: 0.8pt">_____________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; padding-right: 1.8pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Richard Schumacher,</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 9pt 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 8.5pt 0 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt; font-weight: bold">Exhibit Number&nbsp;</TD>
    <TD STYLE="width: 90%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt; font-weight: bold">Exhibit Description&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">99.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 11pt">Press release dated February 12, 2013 of Pressure BioSciences, Inc. furnished herewith.</TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 9pt 0 0">&nbsp;</P>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "form8k_boardchange020713.htm", "secsgml_size_bytes": 18701}]
{"company-data": {"conformed-name": "PRESSURE BIOSCIENCES INC", "cik": "0000830656", "assigned-sic": "3826", "irs-number": "042652826", "state-of-incorporation": "MA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-21615", "film-number": "13598780"}, "business-address": {"street1": "14 NORFOLK AVENUE", "city": "SOUTH EASTON", "state": "MA", "zip": "02375", "phone": "5082301828"}, "mail-address": {"street1": "14 NORFOLK AVENUE", "city": "SOUTH EASTON", "state": "MA", "zip": "02375"}, "former-company": {"former-conformed-name": "BOSTON BIOMEDICA INC", "date-changed": "19960812"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 7, 2013
PRESSURE BIOSCIENCES, INC.
(Exact Name of Registrant as Specified
in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction
of Incorporation)
0-21615
04-2652826
(Commission File Number)
(IRS Employer Identification No.)
14 Norfolk Avenue, South Easton, MA
02375
(Address of Principal Executive Offices)
(Zip Code)
(508) 230-1828
(Registrant's Telephone Number,
Including Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 7, 2013, R. Wayne Fritzsche
resigned as a director of Pressure BioSciences, Inc. (the "Company"). Mr. Fritzsche informed the Board of Directors
(the "Board") of the Company that he was resigning to pursue full-time employment with the Company and that his reasons
for resigning were not the result of any disagreement with the Company. The Board accepted Mr. Fritzsche's resignation.
Pursuant to a recommendation by the Nominating
Committee of the Board, on February 7, 2013 the Board appointed Dr. Michael S. "Mickey" Urdea as a director to fill
the vacancy created by Mr. Fritzsche's resignation, effective as of February 8, 2013. Dr. Urdea will be a Class III director
with a term expiring at the Company's 2014 annual meeting of shareholders.
Dr. Urdea will receive an annual Board retainer in the amount of
$30,000. Dr. Urdea will also receive $20,000 annually to develop and lead the Company's Scientific Advisory Board (the "SBA").
Dr. Urdea has agreed to accrue such fees until such time in the future that the Board determines that the overall financial and
cash position of the Company will allow payments of such amounts. The Company and Dr. Urdea have further agreed that in lieu of
payment of a portion of his annual Board and SBA related fees for his first year of service, $12,500 of the annual Board retainer
and $10,000 of the annual SBA related fees would be converted into the Company's private placement of units consisting of
Series J Convertible Preferred Stock and warrants to purchase restricted common stock pursuant to the terms of the private placement.
In addition, as a non-employee director, Dr. Urdea was granted options to purchase 25,000 shares of the Company's common
stock upon appointment as a director, which options vested immediately upon grant, and 25,000 restricted shares of the Company's
common stock, which restricted shares will vest on a monthly basis during his first year of service.
Dr. Urdea has devoted his 30-year career
to human diagnostics in a variety of capacities. He has been involved in the discovery of new biomarkers, the development of new
technologies for biomarker discovery, validation and commercialization, diagnostic test development, manufacturing and marketing,
and the management of companies involved in these activities. Dr. Urdea founded and is a Managing Partner for Halteres Associates,
a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based
diagnostics company involved in preventative personalized medicine. Tethys' first product was the protein-based PreDx Diabetes
Risk Score Test, which was introduced in 2008. Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for
Health, an organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. He serves
as an expert consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number
of biotechnology, diagnostics, venture capital and philanthropic organizations.
Prior to his current business activities,
Dr. Urdea founded the Nucleic Acid Diagnostics group at Chiron Corporation, and with colleagues, invented branched DNA molecules
for amplification of signal in nucleic acid complexes. Application of this technology resulted in the first commercial products
for quantification of human hepatitis B, hepatitis C, and human immunodeficiency viruses (HBV, HCV, and HIV, respectively). He
then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He was also a member
of the Bill and Melinda Gates Foundation Diagnostic Forum.
Dr. Urdea is an author on nearly 200
peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued
and pending patents. He received his BS
in Biology and Chemistry from Northern
Arizona University in Flagstaff and his Ph.D in Biochemistry from Washington State University in Pullman.
A copy of the press release that the Company issued on February
12, 2013 announcing the appointment of Dr. Urdea is attached hereto as Exhibit 99.1.
Item 9.01 	Financial Statements and Exhibits
(d)
Exhibits
Exhibit Number
Exhibit Description
99.1
Press release dated February 12, 2013 of Pressure BioSciences, Inc. furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: February 12, 2013
PRESSURE BIOSCIENCES, INC.
/s/Richard Schumacher
By:
_____________________________
Richard Schumacher,
Chief Executive Officer
EXHIBIT INDEX
Exhibit Number
Exhibit Description
99.1
Press release dated February 12, 2013 of Pressure BioSciences, Inc. furnished herewith.